Full-Time
Manager – Software Development Engineering
Posted on 3/13/2025
Clairo
5,001-10,000 employees
Generates clinical evidence for trials
No salary listed
Senior, Expert
Bengaluru, Karnataka, India
Hybrid working model; specific number of in-office days not mentioned.
- Bachelor’s degree in Computer Science or related field, or equivalent experience.
- 7+ years of experience in software development, with a track record of managing teams.
- Experience in a regulated environment (ISO 9001, FDA 21 CFR Part 11).
- Strong skills in prioritizing multiple projects in a fast-paced environment.
- Knowledge of SQL, Object-Oriented Programming, and software development tools (e.g., Visual Studio, GitLab, JIRA).
- Familiarity with Agile SCRUM, Waterfall, or Kanban methodologies.
- A passion for continuous process improvement.
- Lead the development of clinical trial data collection applications.
- Collaborate with cross-functional teams to deliver complex, customized solutions for clients.
- Work with Product Development to shape the architectural direction of our products.
- Oversee operational readiness tasks, including pilot projects and internal validation.
- Ensure compliance with regulatory standards and maintain SOPs & SWIs.
- Drive improvements in project delivery metrics: productivity, cost, delivery, and quality.
- Communicate effectively across teams and departments, presenting technical decisions and driving consensus.
- Mentor and develop team members, fostering a collaborative and productive work environment.
- Influence the adoption of architecture, design, and technology standards.
- Lead the team through project challenges, ensuring timely resolution and oversight.
Clario specializes in generating clinical evidence for medical research and trials. Their approach combines extensive scientific knowledge with a wide-ranging technology platform that supports various types of clinical trials, including decentralized, hybrid, and site-based formats. Clario's operations are backed by nearly 50 years of experience, during which they have participated in 19,000 clinical trials and achieved 870 regulatory approvals. This extensive experience allows them to provide reliable and comprehensive data to their partners. Unlike many competitors, Clario offers a Trial Anywhere™ portfolio, which enables flexibility in conducting trials across different settings and locations. The company's goal is to empower partners in the healthcare industry to improve patient outcomes by providing high-quality clinical evidence.
Company Size
5,001-10,000
Company Stage
Growth Equity (Venture Capital)
Total Funding
$29.9M
Headquarters
London, United Kingdom
Founded
1972
Simplify's Take
What believers are saying
- Acquisition of NeuroRx enhances Clario's neuroscience capabilities and expertise.
- FDA clearance of SpiroSphere® with wireless ECG streamlines data collection in trials.
- Clario's $10B IPO filing indicates strong market expansion and investment potential.
What critics are saying
- Integration challenges from acquiring NeuroRx and WCG's eCOA business may arise.
- AI partnership with PathAI could face algorithmic bias and data privacy issues.
- Wireless ECG device reliability and data security pose potential compliance risks.
What makes Clairo unique
- Clario offers a broad endpoint technology platform for diverse clinical trial models.
- Trial Anywhere™ enables decentralized, hybrid, and site-based clinical trials with rich evidence.
- Clario's nearly 50 years of experience ensures expertise in clinical trial data solutions.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Competitive and equitable total rewards package
Physical, mental and financial health and wellness
Flexible working approach
Company News
Clario, a Philadelphia-based provider of endpoint data solutions to the clinical trial industry, has acquired NeuroRx, a Montreal-based provider of imaging analysis on multiple sclerosis.
Clario, a leader in endpoint data solutions for clinical trials, has acquired NeuroRx, an imaging analysis expert in multiple sclerosis. This acquisition enhances Clario's neuroscience capabilities. NeuroRx's founder, Douglas Arnold, M.D., will join Clario as Senior Scientific Advisor. Clario also plans to acquire WCG’s eCOA business, further strengthening its neuroscience expertise.
Acquisition of WCG's electronic clinical outcome assessments (eCOA) business will expand Clario's scientific expertise and offerings in neurosciencePHILADELPHIA, March 10, 2025 /PRNewswire/ -- Clario, a leading provider of endpoint data solutions to the clinical trial industry, today announced they have entered into a definitive agreement to acquire the eCOA business of WCG, a leader in providing solutions that measurably improve and accelerate clinical research. Electronic clinical outcomes assessments (eCOA), in addition to paper assessments, are used to evaluate the safety and efficacy of new drugs by measuring how a clinical trial participant feels or functions. WCG's eCOA operations offer robust, full-service clinical expertise and specialized functionality, particularly in neurology, psychiatry, neuropathic pain, and rare diseases
PHILADELPHIA - October 10, 2024 - Clario, a leading provider of endpoint data solutions to the clinical trials industry, is excited to announce a strategic partnership with PathAI, a leader in AI-powered digital pathology solutions aimed at improving diagnostic accuracy and efficiency.
Title: "Clario, Drug Trial Software Maker, Files Confidential IPO Dossier" Content: Clario, a software maker for drug trials, has filed a confidential dossier for an IPO, aiming for a valuation of over $10 billion, according to Bloomberg News.